ALERT!
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Objective Discrepancies in the MARS-2 Trial: An Interview with David Waller
At the 2023 EACTS Annual Meeting, CTSNet Editor in Chief Joel Dunning and CTSNet senior editors set out to interview the most knowledgeable CT surgeons from around the world. Stay tuned for more interviews from the meeting.
CTSNet Editor in Chief Joel Dunning spoke with Dr. David Waller about the MARS-2 mesothelioma clinical trial. They discussed various discrepancies in the trial that make it difficult to apply to real-world mesothelioma treatment. They also considered what should be changed in the future MARS-3 clinical trial to avoid those inconsistencies.
Dr. Waller is a thoracic surgeon at St. Bartholemew’s hospital in London, UK. He is a leading contributor to mesothelioma surgery and an expert on various topics in thoracic surgery. For more from Dr. Waller, watch his Birmingham Review Course session on the role of surgery for early-stage lung cancer treatment.
Disclaimer
The information and views presented on CTSNet.org represent the views of the authors and contributors of the material and not of CTSNet. Please review our full disclaimer page here.
Printer-friendly
